open access

Vol 14, No 6 (2019)
Editorial
Get Citation

Editorial

Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2019.0118
·
Folia Cardiologica 2019;14(6).

open access

Vol 14, No 6 (2019)
Editorial

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Editorial

Journal

Folia Cardiologica

Issue

Vol 14, No 6 (2019)

DOI

10.5603/FC.2019.0118

Bibliographic record

Folia Cardiologica 2019;14(6).

Authors

Beata Wożakowska-Kapłon

References (12)
  1. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii — Instytut im. Marii Skłodowskiej-Curie. http://onkologia.org (2018).
  2. Montgomery DA, Krupa K, Cooke TG. Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer. 2007; 97(12): 1632–1641.
  3. McTiernan A. Behavioral risk factors in breast cancer: can risk be modified? Oncologist. 2003; 8(4): 326–334.
  4. Charakterystyka produktu leczniczego rybocyklib — Kisquali. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_pl.pdf (14.02.2020).
  5. Choroby onkologiczne — Ministerstwo Zdrowia. https://www.gov.pl/web/zdrowie/choroby-onkologiczne (2019).
  6. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016; 375(18): 1738–1748.
  7. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018; 36(24): 2465–2472.
  8. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018; 19(7): 904–915.
  9. Im S-A, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019; 381(4): 307–316.
  10. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020; 382(6): 514–524.
  11. A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE). https://clinicaltrials.gov/ct2/show/NCT03701334?cond=natalee&draw=1&rank=1 (14.02.2020).
  12. Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer (CORALLEEN). https://clinicaltrials.gov/ct2/show/NCT03248427 (14.02.2020).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl